The intracorporeal injection of papaverine (ICP) is now a well recognized therapeutic option in the management of impotence. The current treatment of advanced prostatic carcinoma causes erectile failure. Although intracorporeal papaverine can induce erections in these men, libido is also reduced so that the role of ICP is limited to those men complying with the wishes of a highly motivated partner.
Introduction
The aim of the standard treatment of symptomatic advanced prostatic cancer is androgen withdrawal either by surgical or medical castration. These therapeutic methods are effective in providing useful palliation in approximately 80% of patients often for periods of several years. Unfortunately a common side-effect of this treatment is erectile impotence which develops in most men potent before the commencement of treatment. The use of intracorporeal papaverine injections (ICP) is well established in the treatment of various forms of erectile failure'P, The aim of this study was to assess the response to, and hence the possible use of, intracorporeal papaverine injections in those men rendered impotent by their therapeutic castration.
Patients and methods
At this centre' all men presenting with metastatic prostatic carcinoma were randomized into a three armed multicentre trial (Schering 262) for the comparative evaluation of cyproterone acetate (Cyprostat, Schering) and the LHRH analogue Goserelin (Zoladex, ICI) alone and in combination. Each patient was questioned about his potency and sexual drive at presentation and, before treatment had started, baseline levels of serum testosterone and luteinizing hormone were measured. After commencing hormone therapy patients were followed up at monthly intervals with regular re-appraisal of sexual function and assessment of hormone levels. Those men who subsequently developed impotence were counselled regarding the use of ICP with the aim of entering a self-injection programme if they responded. Patients were reassessed after 2 weeks allowing time for consultation with his sexual partner. Those who expressed an interest in selfinjection were administered a sample intracorporeal dose of 30 mg of papaverine. If a poor response occurred either 60 or 90 mg were injected at subsequent review. A satisfactory response was judged to be the production of penile tumescence of sufficient rigidity to allow penetration and hence sexual intercourse.
Results
All patients had serum testosterone levels within the castrate range « 2 nmolll) one month after commencing treatment. Seventy-four patients have been entered into the metastatic prostate cancer trial and of these only 34 (46%) were potent prior to treatment, 31 of these 34 (91%) subsequently developed impotence on treatment. Only 17 of the 31 patients expressed an initial interest in joining the papaverine self-injection programme of whom only 10 requested a trial dose after consulting their partner.
Of these patients, nine achieved a satisfactory response as previously defined, five of whom were motivated to proceed to self injection. Only two continue to use papaverine for the purpose of sexual intercourse. Those who withdrew from the selfinjection programme did so for apparently different reasons. One man left his partner and had no further need for papaverine. The second man lost sexual interest as time went by and the third found the procedure increasingly unsatisfactory, again possibly as a result of reduced sexual interest. The two continuing to self-inject had considerably younger wives.
Discussion
We have confirmed in this study that the majority of men on hormonal manipulation designed to reduce the serum testosterone to castrate levels are rendered impotent. We have shown however that intracorporeal papaverine can produce a satisfactory erection in most men in whom this occurs. It is therefore feasible to offer self-injection to all men potent prior to the commencement of hormone therapy for prostatic cancer. Despite the effectiveness of ICP a large proportion of such men will not be interested in self-injection due to the associated loss of libido. It is significant in this respect that the two men who continued to inject did so because of the motivation of a younger partner rather than the retention of sexual interest by the patient himself. It would seem from this study that although intracorporeal papaverine self-injection may be offered only a few will be sufficiently motivated by their partners to pursue this line of therapy.
